ClinicalTrials.gg
Not yet recruitingNCT07505979Updated Apr 13, 2026

SMART Trial: Cognitive Sparing Brain Radiotherapy for Multiple Brain Metastases

A Phase 2 interventional study of SRS and CS-WBRT in Brain Metastases From Solid Tumors, sponsored by National Taiwan University Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by National Taiwan University Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Brain Neoplasms by National Taiwan University Hospital — 4 open to participants now, 4 under way, none of them phase 3. Brain Neoplasms · National Taiwan University Hospital.

Planned enrollment
5th of 11
90 · median 80
Started
2026
the only one that year
Phase 2
6 of 15
1 open now
Registered
15th of 15
by date

Among the 15 studies in Brain Neoplasms by National Taiwan University Hospital, this one is the 5th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2026, is one of 6 in phase 2, and was the 15th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

4 of the 15 studies in Brain Neoplasms by National Taiwan University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Brain Neoplasms by National Taiwan University Hospital, or all of them as a file.
02

Study summary

The goal of this phase II randomized trial is to determine if Stereotactic Radiosurgery (SRS) or Cognitive Sparing WBRT (CS-WBRT) better preserves neurocognitive function than standard Hippocampal Avoidance WBRT (HA-WBRT) in patients with multiple brain metastases ( $\ge6$ lesions).

The main questions it aims to answer are:

  • Which treatment best preserves cognitive function (memory and executive tasks) at 6 months post-intervention?
  • Can sparing the left hippocampus and corpus callosum (CS-WBRT) or using focal SRS reduce cognitive decline compared to bilateral sparing? Comparison Groups

Researchers will compare three arms to evaluate their impact on cognition and disease control:

  • Arm A (SRS): Focal high-dose radiation (15-20 Gy in 1 fraction) to intracranial lesions.
  • Arm B (CS-WBRT): Whole-brain radiation (30 Gy in 10 fractions) sparing the left hippocampus and corpus callosum plus Memantine.
  • Arm C (HA-WBRT): Whole-brain radiation (30 Gy in 10 fractions) with bilateral hippocampal avoidance plus Memantine.

Participant Tasks

Participants will:

  • Complete neurocognitive and neuropsychological tests (HVLT-R, TMT, COWAT, CANTAB) at baseline and follow-up.
  • Undergo contrast-enhanced brain MRI for planning and tracking tumor progression.
  • Take Memantine HCL daily for 24 weeks if assigned to the WBRT arms (B or C).
  • Provide blood samples for biomarker and genetic analysis (e.g., APOE, Tau).
  • Undergo olfactory function testing and complete quality-of-life questionnaires.
03

Conditions studied

  • Brain Metastases From Solid Tumors

Browse trials for

Keywords

  • Brain metastases
  • Cognitive Preservation
  • Hippocampal Avoidance Whole Brain Radiotherapy
  • Stereotactic Radiosurgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with a histologic diagnosis of non-hematopoietic and radiographic evidence of
  2. Patients with brain metastasis outside a 5-mm margin around either hippocampus or corpus callosum on gadolinium contrast-enhanced MRI obtained within 30 days prior to registration
  3. Patients with 6 or more active or progressive brain metastases that have not been treated by radiotherapy or radiosurgery
  4. No evidence of diffuse on gadolinium-enhanced MRI within 30 days prior registration
  5. Age ≥ 18 years
  6. Performance Status ≥ 60%
  7. ≥ 6 months.
  8. Women of and male participants must practice adequate
  9. Patients must be able to comply with the study protocol and follow-up schedules and provide study-specific

Exclusion criteria

Exclusion Criteria:

  1. Prior radiotherapy to brain or radiosurgery to > 5 intracranial lesion(s)
  2. Clinical diagnosis of symptomatic metastsases
  3. to MR imaging such as implanted metal devices or foreign bodies, severe claustrophobia
  4. Severe, active comorbidities which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and adverse events of the protocol, or limit compliance with study requirements, defined as follows:

    1. Uncontrolled active infection requiring intravenous antibiotics at the time of registration
    2. Transmural myocardial infarction ≤ 6 months prior to registration
    3. Unstable angina or congestive heart failure requiring hospitalization ≤ 6 months prior to registration
    4. Life-threatening uncontrolled cardiac arrhythmias
    5. Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
    6. exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
    7. Uncontrolled psychiatric disorder
  5. Will receive any other investigation agent or chemotherapy during cranial radiotherapy or radiosurgery
  6. Current use of Memantine HCL or Allergy to Memantine HCL
  7. Women of and male participants who are sexually active and not willing/able to use medically acceptable forms of ; this exclusion is necessary because the radiation treatment involved in this study may be significantly teratogenic
  8. Pregnant or breast-feeding women
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    SRS

    Radiation: SRS

  • Experimental
    CS-WBRT

    Radiation: CS-WBRT

  • Active comparator
    HA-WBRT

    Radiation: HA-WBRT

Interventions

  • RadiationSRS

    Focal high-dose radiation (15-20 Gy in 1 fraction) to intracranial lesions

  • RadiationCS-WBRT

    Conformal Whole Brain Radiotherapy 3000 cGy in 10 fractions with Left Hippocampal Avoidance \& Corpus Callosum Sparing using RapidArc

  • RadiationHA-WBRT

    Conformal Whole Brain Radiotherapy 3000 cGy in 10 fractions with Bilateral Hippocampal Avoidance using RapidArc

06

What researchers measure

Primary outcomes

  1. Preservation in neurocognitive function at 6 months after the start of brain radiotherapy for patients with multiple brain metastases

    The primary endpoint is defined as the z-scores of changes in HVLT-R memory score, and CANTAB® tasks at 6 months after the start of cranial radiotherapy or radiosurgery for multiple brain metastases. Investigators hypothesize that at least one of the three treatment arms will outperform the others in preserving neurocognitive function at 6 months

    Time frame: From enrollment to 6 months after the start of brain radiotherapy

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Apr 2029, 36 months later.

Of 208 non-industry phase 2 interventional studies under Brain Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 100. This study's planned 36 months is below that.

Counting every sponsor, half of 252 studies reached it within 61 months; a quarter within 38 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Apr 1, 2026
StartEst.
Apr 2026
Primary completionEst.
Apr 2029
CompletionEst.
Apr 2031
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07505979
Responsible party
Sponsor
First posted
Apr 1, 2026
Start date
Apr 2026 (estimated)
Primary completion
Apr 2029 (estimated)
Completion
Apr 2031 (estimated)
Last update
Apr 13, 2026

Study contacts

Wen-Chi Yang, MD, PhD
Contact
claireds23@ntuh.gov.tw
+886912545812

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion